The Role of DNA Methyltransferases in Urinary System Diseases Authors: Wei Dong, Shengbin Pei, Dacheng Zhu, Cheng Zeng, Yue Qiu, Yuxin Wu, Xinlu Jia, Siqi Zhang, Chao Li, Wenjuan Zhang, Wenbing Zhang, Zhihua Chen Published: 2025 ABSTRACT ABSTRACTDNA methylation is a crucial epigenetic regulatory mechanism that can modify chromatin structure, DNA conformation, DNA stability, and the interactions between DNA and proteins, thereby controlling gene expression. It has been shown to play a significant role in pathological processes such as fibrosis and tumorigenesis. DNA methyltransferases (DNMTs) are key players in this process. This study aims to investigate the role of DNMTs in the development of urinary system diseases, such as renal fibrosis and prostate cancer, revealing how they regulate gene expression by modulating DNA methylation levels, thereby significantly promoting the progression of these diseases. Additionally, this review explores their potential clinical applications as therapeutic targets, which may offer new research directions for understanding the pathogenesis and treatment of urinary system diseases in the future.Keywords: DNA methylation, DNA methyltransferases, epigenetic, therapy, urinary system diseases Abbreviations 5‐methylcytosine ATP‐binding cassette subfamily C member 4 ATRX‐DNMT3‐DNMT3L acute kidney injury aldehyde dehydrogenase 1 family member A2 alpha‐smooth‐muscle actin bromo‐adjacent homology clear cell renal cell carcinoma cyclin‐dependent kinase inhibitor 2A chronic kidney disease calcium oxalate monohydrate collapsin response mediator protein 4 cytochrome P450‐family 4‐subfamily a‐polypeptide 10 death‐associated protein kinase diabetic kidney disease deleted in liver cancer 1 DNMT1‐associated protein 1 DNA methyltransferases endoplasmic reticulum‐interacting protein 24 epithelial–mesenchymal transition embryonic stem cells glutamate receptor ionotropic AMPA type subunit 3 glutathione s‐transferases P1 hypoxia inducible domain family member 1A inducible nitric oxide synthase interferon regulatory factor 6 interferon regulatory factor 8 kinesin family member 20B Kruppel‐like factor 4 long noncoding RNAs lower urinary tract symptoms muscle invasive bladder cancer N‐myc downstream regulated gene 2 nuclear factor κB opioid‐binding protein/cell adhesion molecule‐like polo‐like kinase 1 phosphatase and tensin homolog domain family protein 1 isoform A renal cell carcinoma renal erythropoietin cells replication foci targeting sequence reactive oxygen species solute carrier organic anion transporter family member 1A1 mothers against decapentaplegic homolog 7 5‐α reductase type 2 type 1 diabetes mellitus type 2 diabetes mellitus tuberous sclerosis complex 2 urinary tract infections unilateral ureteral obstruction von Hippel‐Lindau–Ras association WW domain‐containing oxidoreductase Introduction Epigenetics is a genetic discipline that investigates the regulation of gene expression without alterations in DNA sequence. Among these modifications, DNA methylation is particularly crucial. DNA methyltransferases (DNMTs) catalyze the addition of methyl groups to DNA bases, facilitating DNA methylation [1]. As early as the 1960s, scientists discovered the presence of DNMTs in bacteria. In 1988, they successfully cloned mouse DNMT1, marking the discovery of the first mammalian DNMT [2, 3]. Subsequently, DNMTs have emerged as a prominent subject within epigenetics with an expanded family tree [4]. As early as the 1960s, scientists discovered the presence of DNMTs in bacteria. In 1988, they successfully cloned mouse DNMT1, marking the discovery of the first mammalian DNMT [5, 6]. The enigma surrounding DNMTs is gradually unraveling. Urinary system diseases include a variety of conditions that affect the kidneys, ureters, bladder, urethra, and related structures. These range from infections, stones, and tumors to congenital anomalies and functional disorders [7, 8]. At present, urologic tumors pose a substantial global health challenge, characterized by high incidence and mortality rates across the world. For example, kidney cancer alone gives rise to about 295,000 new cases every year, leading to approximately 134,000 deaths globally. This accounts for nearly 2% of all cancer diagnoses and deaths worldwide [9, 10]. Additionally, the prevalence of chronic kidney disease (CKD) has escalated over the past two decades and now contributes to an annual loss of 1.35% in disability‐adjusted life years at an increasing rate of 1% [11]. Furthermore, nearly half of the estimated 400 million individuals worldwide diagnosed with type 2 diabetes exhibit evidence indicative of diabetic nephropathy [12]. The mounting evidence underscores that urinary system diseases are escalating into a more widespread concern for humanity. Yet, the efficacy of existing treatments for these ailments fluctuates, often hindered by drug resistance, intricate surgeries, and subsequent complications, which collectively erect substantial barriers to attaining optimal therapeutic results. Thus, delving into DNMTs as a prospective focal point for identifying new treatment targets for urinary system diseases emerges as a vital endeavor. In this review, we first provide a concise explanation of the concept of DNMTs. We then summarize the functional and regulatory roles of DNMTs in urinary system diseases. Additionally, we explore their potential clinical applications and future perspectives in these diseases. DNMTs DNMTs are a crucial family of enzymes responsible for the methylation modification of DNA molecules and play a pivotal role in the process of DNA methylation “writing” [6]. These enzymes modify the epigenetic mark of the genome by attaching a methyl group to the fifth carbon atom of the cytosine ring on the DNA strand, resulting in the formation of 5‐methylcytosine (5mC) [13]. The activity and function of DNMTs significantly contribute to normal cellular physiological processes and are intricately associated with the onset and progression of numerous diseases [1]. Overview of DNMTs The human genome encodes five DNMTs, namely DNMT1, DNMT2, DNMT3A, DNMT3B, and DNMT3L (Figure 1). Among them, DNMT1, DNMT3A, and DNMT3B are classical cytosine‐5 methyltransferases responsible for adding methylation marks to genomic DNA [1]. In contrast, both DNMT2 and DNMT3L are nonclassical methyltransferases lacking catalytic activity towards DNA [14, 15]. Typically, a typical structure of a DNMT consists of an N‐terminal regulatory domain and a C‐terminal catalytic domain [16]. However, an exception is observed in the case of the tRNA methyltransferase—DNMT2, which solely comprises the catalytic domain [17]. All three classical DNMTs (DNMT1, DNMT3A, and DNMT3B) contain the catalytic domain that usually encompasses several key functional regions, including the active site for methylation transferase activity as well as the DNA binding site required for specific recognition of target DNA sequences, ensuring accurate positioning during methylation modification events [18]. By regulating gene expression levels, DNMTs play crucial roles in various biological processes influencing cell differentiation status and fate [19]. Structure and function of DNA methyltransferases. (a) Structure of members of the DNMT family. (b) Changes in cytosines during DNA methylation: DNMTs methylate the fifth carbon atom of cytosine using S‐adenosylmethionine (SAM) as the methyl donor, resulting in the formation of 5‐mC. (c) Different ways in which DNMTs modify DNA: DNMT1 is responsible for the methylation of hemimethylated DNA, whereas DNMT3A and DNMT3B are accountable for the methylation of unmethylated DNA. SAH: S‐adenosine‐l‐homocysteine. Image created with Adobe Illustrator (https://www.adobe.com/products/illustrator.html). DNMT1 The DNMT1 protein has a length of approximately 1616 amino acids (aa) and a molecular weight of around 183 kilodaltons (kDa). Its coding gene is located on chromosome 19p13.2, with a total protein coding region spanning 4851 base pairs (bp) [20]. The N‐terminal domain of DNMT1 comprises the following domains: the DNMT1‐associated protein 1 (DMAP1) binding domain, replication foci targeting sequence (RFTS), CXXC domain (zinc finger domain), and two conserved bromo‐adjacent homology (BAH) domains [19]. Typically, DNMT1 functions as a primary maintenance methyltransferase responsible for preserving DNA methylation patterns that have already been established [21]. During this process, DNMT1 associates with the DNA synthetase complex and transfers the original methyl mark from parental DNA to nascent DNA strands during replication, thereby ensuring the stability of cellular genetic information post cell division [20, 22]. Additionally, apart from its role in DNA replication, DNMT1 also plays a crucial role in regulating various cellular processes such as gene expression and gene silencing. Furthermore, DNMT1‐mediated epigenetic modifications are closely associated with the occurrence and progression of numerous diseases [23]. DNMT2 The DNMT2 protein has a length of 391 aa and a molecular weight of approximately 45 kDa. Its coding gene is located on chromosome 10p14 [24]. DNMT2 is an ancient DNMT that encompasses all the conserved catalytic motifs of a cytosine‐5 DNMT, but its primary methyltransferase activity targets tRNA rather than DNA [25]. DNMT2 facilitates the formation of 5‐methyluracil (5mC) on tRNA molecules and functions as a tRNA methyltransferase. It predominantly operates in the cytoplasm, where its mediated epigenetic modification significantly influences tRNA stability, associated gene expression, and protein translation [17, 26]. DNMT3 The DNMT3A protein has a length of approximately 990 aa and a molecular weight of around 130 kDa. Its coding gene is located on chromosome 2p23, with a total protein coding region spanning 2172 bp. On the other hand, the DNMT3B protein is about 853 aa long and has a molecular weight of approximately 95 kDa. Its coding gene can be found on chromosome 20q11.21, encompassing a total protein coding region of 2538 bp [27]. DNMT3a and DNMT3b share similar N‐terminal domains, including a Pro‐Trp‐Trp‐Pro (PWWP) domain, an ATRX‐DNMT3‐DNMT3L (ADD) domain, and a C‐terminal catalytic domain [19]. In contrast to DNMT1, both DNMT3a and DNMT3b are commonly classified as de novo methyltransferases that reversibly methylate unmethylated DNA [21, 28]. Therefore, the epigenetic activities mediated by DNMT3A and DNMT3B play crucial roles in determining gene expression patterns in cells and tissues while maintaining genomic variability during embryonic development and germ cell development [27, 29]. Additionally, these proteins also contribute to the occurrence and progression of various diseases such as hereditary disorders, neurological conditions, immune diseases, and tumors [1, 29]. The DNMT3L protein has a length of approximately 386 aa and a molecular weight of around 44 kDa. Its coding gene is situated on chromosome 21q22.3 [19, 30]. In contrast to DNMT3A and DNMT3B, DNMT3L itself lacks direct DNMT activity but typically functions as a crucial cofactor for the DNMT3 enzyme, enhancing the catalytic activity of both DNMT3A and DNMT3B toward DNA substrates [31]. Moreover, DNMT3L is recognized as a pivotal regulator of self‐renewal and differentiation in embryonic stem cells (ESCs), with its expression level exerting an influence on the establishment and maintenance of DNA methylation patterns in ESCs, thereby impacting gene expression and cellular fate [19, 32]. Overview of DNMT Inhibitors Recently, DNMTs have garnered significant attention as potential therapeutic targets. Consequently, scientists have developed and investigated inhibitors of DNMTs to modulate epigenetic regulation and gene expression by disrupting DNA methylation modification. Certain DNMT inhibitors have demonstrated promising efficacy in clinical trials, making them a viable choice for novel treatment strategies (Table 1). Table 1DNMT inhibitors.Drug namesOrganizationsDrug typesDrug targetsMechanismIndicationsDevelopment phaseLarsucosterolVirginia Commonwealth UniversitySmall‐molecule drugDNMTsDNMT inhibitors Alcoholic Hepatitis Nonalcoholic Steatohepatitis Clinical Phase II(S)‐Perillyl Alcohol TemozolomideNeOnc Technologies Inc.Small‐molecule drugDNMTsDNMT inhibitors Advanced Renal Cell Carcinoma IDH Mutant Astrocytoma Clinical Phase IIAza‐T‐dCydNational Cancer InstituteSmall‐molecule drugDNMTsDNMT inhibitors Cancer Hemic and Lymphatic Diseases Clinical Phase IMC3343Alma Mater Studiorum—Università di BolognaSmall‐molecule drugDNMTsDNMT inhibitorsCancerPreclinicalMetalmeta analog (Sapienza Università di Roma)Sapienza University of RomeSmall‐molecule drugDNMTsDNMT inhibitorsCancerPreclinicalNPEOC‐DACUniversity of Southern CaliforniaSmall‐molecule drugDNMTsDNMT inhibitorsCancerPreclinicalTemozolomide Hexyl EsterTasly Pharmaceutical Group Co. Ltd.Small‐molecule drugDNMTsDNMT inhibitors Cancer Diseases of the Nervous System Clinical ApplicationXB‐05University of LouisvilleSmall‐molecule drugDNMTsDNMT inhibitorsCancerDrug DiscoveryKM‐101Kainos Medicine Inc.Small‐molecule drugDNMTsDNMT inhibitorsCancerDrug DiscoveryTriclabendazoleNovartis Pharmaceuticals Corp.Small‐molecule drugDNMT1DNMT1 inhibitorsSchistosomiasisApproved for listingDecitabine Merck Sharp & Dohme Corp. Astex Pharmaceuticals Inc. Small‐molecule drugDNMT1DNMT1 inhibitors Cancer Anemia, Refractory Approved for listingAzacitidine Celgene Corp. Takeda Pharmaceutical Co. Ltd. Small‐molecule drugDNMT1DNMT1 inhibitorsJuvenile Myelomonocytic LeukemiaApproved for listingEF‐009Everfront Biotech Inc.Small‐molecule drugDNMT1DNMT1 inhibitorsCancerClinical Phase IINTX‐301The University of Alabama at BirminghamSmall‐molecule drugDNMT1DNMT1 inhibitorsCancerClinical Phase IIOP‐2100Ohara Pharmaceutical Co. Ltd.Small‐molecule drugDNMT1DNMT1 inhibitors Chronic Myelomonocytic Leukemia Refractory High Risk Myelodysplastic Syndrome Clinical Phase IAST‐081Aston SCISmall‐molecule drugDNMT1DNMT1 inhibitorsAcute Myeloid LeukemiaClinical Phase IGSK4172239DGSK PlcSmall‐molecule drugDNMT1DNMT1 inhibitorsAnemia, Sickle CellClinical Phase IDNMT1 inhibitors (Sichu University)West China HospitalSmall‐molecule drugDNMT1DNMT1 inhibitorsCancerPreclinicalMS‐9024Icahn School of Medicine at Mount SinaiSmall‐molecule drugDNMT1DNMT1 inhibitorsCancerPreclinicalRG108German Cancer Research CenterSmall‐molecule drugDNMT1DNMT1 inhibitorsCancerPreclinicalGW623415XGlaxoSmithKline Biologicals SASmall‐molecule drugDNMT1DNMT1 inhibitorsAcute Myeloid LeukemiaPreclinicalOR‐2100National Cancer Center Research InstituteSmall‐molecule drugDNMT1DNMT1 inhibitorsHematologic NeoplasmsPreclinicalGSK3830052GlaxoSmithKline Biologicals SASmall‐molecule drugDNMT1DNMT1 inhibitorsAcute Myeloid LeukemiaPreclinical5AdCLSU Health Sciences CenterSmall‐molecule drugDNMT1DNMT1 inhibitorsProstatic CancerPreclinicalNSC‐801845National Cancer InstituteSmall‐molecule drugDNMT1DNMT1 inhibitorsCancerPreclinicalWK‐23Guangzhou University of Chinese MedicineSmall‐molecule drugDNMT1DNMT1 inhibitorsCancerPreclinicalSGI‐1027Astex Pharmaceuticals Inc.Small‐molecule drugDNMT1DNMT1 inhibitorsCancerPreclinicalTdCydNational Cancer InstituteSmall‐molecule drugDNMT1DNMT1 inhibitorsAdvanced Malignant Solid NeoplasmClinical Phase I (pause)CN116143625 Central South University Tsinghua University Small‐molecule drugDNMT1DNMT1 inhibitorsCancerDrug DiscoveryUS20220136019University of South FloridaSmall‐molecule drugDNMT1DNMT1 inhibitorsInfectious DiseasesDrug DiscoveryCN116535393Hebei Kangtai Pharmaceutical Co. Ltd.Small‐molecule drugDNMT1DNMT1 inhibitors Cancer Myelodysplastic Syndromes Drug DiscoveryAptadir Ce‐49AptaDir Therapeutics SrlAntisense oligonucleotidesDNMT1DNMT1 inhibitorsMyelodysplastic SyndromesDrug DiscoveryWO2024156288Shanghai Qizhen Pharmaceutical Technology Co. Ltd.Small‐molecule drugDNMT1DNMT1 inhibitors Dermatophilosis Cancer Drug DiscoveryWO2025006902Dana‐Farber Cancer Institute Inc.Proteolysis‐targeting chimeras (PROTAC)DNMT1DNMT1 inhibitorsCancerDrug DiscoveryCN116444501Hebei Kangtai Pharmaceutical Co. Ltd.Small‐molecule drugDNMT1DNMT1 inhibitors Myelodysplastic Syndromes Cancer Drug DiscoveryWO2024116094Daiichi Sankyo Co. Ltd.Antibody drug conjugate (ADC)DNMT1DNMT1 inhibitors Cancer Skin and Musculoskeletal Diseases Drug DiscoveryWO2022185160GlaxoSmithKline Intellectual Property Development Ltd.Small‐molecule drugDNMT1DNMT1 inhibitors Cancer Hemic and Lymphatic Diseases Drug DiscoveryMG‐98Mirati Therapeutics Inc.Antisense oligonucleotidesDNMT1DNMT1 inhibitors Cancer Hemic and Lymphatic Diseases Clinical Phase II (pause)GSK‐3685032GlaxoSmithKline (China) R&D Co. Ltd.Small‐molecule drugDNMT1DNMT1 inhibitors Cancer Hemic and Lymphatic Diseases PreclinicalOR‐2003Ohara Pharmaceutical Co. Ltd.Small‐molecule drugDNMT1DNMT1 inhibitors Cancer Hemic and Lymphatic Diseases PreclinicalNT1721City of Hope National Medical CenterSmall‐molecule drugDNMT1DNMT1 inhibitorsAcute Myeloid LeukemiaPreclinicalSGI‐1036Novartis Institutes of Biomedical ResearchSmall‐molecule drugDNMT1DNMT1 inhibitorsAcute Myeloid LeukemiaDrug DiscoveryGSK‐3484862GSK PlcSmall‐molecule drugDNMT1DNMT1 inhibitorsCancerPreclinicalFdCydCity of Hope National Medical CenterSmall‐molecule drugDNMT1DNMT1 inhibitors Cancer Adult Acute Myeloblastic Leukemia Clinical Phase IIQTX‐200 series (Quimatryx)Quimatryx SLSmall‐molecule drugDNMT1DNMT1 inhibitorsNervous System DiseasesDrug DiscoveryDecitabine/CedazuridineOtsuka Pharmaceutical Europe Ltd.Small‐molecule drugDNMT1DNMT1 inhibitorsAcute Myeloid LeukemiaApproved for listingAzacitidine/CedazuridineTaiho Oncology Inc.Small‐molecule drugDNMT1DNMT1 inhibitors Acute Myeloid Leukemia Chronic Myelomonocytic Leukemia Clinical Phase IIIDecitabine/TetrahydrouridineNovo Nordisk A/SSmall‐molecule drugDNMT1DNMT1 inhibitorsAnemia, Sickle CellClinical Phase IIZebularineNational Cancer InstituteSmall‐molecule drugDNMT1DNMT1 inhibitorsCancerPreclinicalCompound (R)‐23a (Shandong University)Shandong UniversitySmall‐molecule drugDNMT1DNMT1 inhibitorsColorectal CancerPreclinicalDNMT/HDAC inhibitors (Shenzhen University)Shenzhen UniversityUnknownDNMT1DNMT1 inhibitorsBreast CancerDrug DiscoveryCM‐444WuXi AppTec (Tianjin) Co. Ltd.Small‐molecule drugDNMT1DNMT1 inhibitorsMultiple MyelomaPreclinicalNSC777586AkiraBio Inc.Chemical drugsDNMT1DNMT1 inhibitorsAnemia, Sickle CellPreclinicalChlorogenic acidSichuan Jiuzhang Biotechnology Co. Ltd.Small‐molecule drugDNMT1DNMT1 inhibitorsCancerClinical Phase IAB1Duke UniversitySmall‐molecule drugDNMT1DNMT1 inhibitorsAnemia, Sickle CellClinical Phase II (pause)Curcumin LiposomalSignPath Pharma Inc.Liposomal drugDNMT1DNMT1 inhibitorsAdvanced cancerClinical Phase IIDY‐46‐2Zhejiang UniversitySmall‐molecule drugDNMT3A DNMT3A inhibitors CancerPreclinicalTargeting‐DNMT3B mRNA therapy (Altamira Therapeutics)Altamira Therapeutics Ltd.mRNADNMT3B DNMT3B inhibitors OsteoarthritisPreclinicalDBICThe Broad Institute Inc.Small‐molecule drugDNMT3B DNMT3B inhibitors CancerPreclinical DNMT inhibitors. Alcoholic Hepatitis Nonalcoholic Steatohepatitis Advanced Renal Cell Carcinoma IDH Mutant Astrocytoma Cancer Hemic and Lymphatic Diseases Cancer Diseases of the Nervous System Merck Sharp & Dohme Corp. Astex Pharmaceuticals Inc. Cancer Anemia, Refractory Celgene Corp. Takeda Pharmaceutical Co. Ltd. Chronic Myelomonocytic Leukemia Refractory High Risk Myelodysplastic Syndrome Central South University Tsinghua University Cancer Myelodysplastic Syndromes Dermatophilosis Cancer Myelodysplastic Syndromes Cancer Cancer Skin and Musculoskeletal Diseases Cancer Hemic and Lymphatic Diseases Cancer Hemic and Lymphatic Diseases Cancer Hemic and Lymphatic Diseases Cancer Hemic and Lymphatic Diseases Cancer Adult Acute Myeloblastic Leukemia Acute Myeloid Leukemia Chronic Myelomonocytic Leukemia DNMT3A inhibitors DNMT3B inhibitors DNMT3B inhibitors DNMT inhibitors can be broadly classified into two categories: nucleotide analogs and non‐nucleotide analogs. Nucleotide analogs primarily consist of cytosine analogs that mimic the structure of DNA bases and competitively bind to DNMTs, thereby inhibiting their catalytic activity [33]. On the other hand, non‐nucleotide analogs encompass oligonucleotide drugs, DNA binders, and SAM cofactor competitors that interfere with the catalytic function of DNMTs through interactions with other domains or relevant targets within DNMTs [34]. Cytosine analogs such as azacytidine (AZA) and decitabine (DAC) have been approved by the FDA for hematological diseases; however, clinical trials indicate limited efficacy against solid tumors [33]. Prominent oligonucleotide drugs like MG98 exhibit certain antitumor effects on renal cell carcinoma (RCC) [35, 36]. In summary, as a crucial class of biologically active small molecules, DNMT inhibitors hold immense significance in both DNA methylation research and disease therapy fields alike. Further studies on DNMTs along with continued exploration into their inhibitors will enhance our understanding regarding their functions and regulatory mechanisms while providing new targets and strategies for treating related diseases. Function of DNMTs in Various Types of Urinary System Diseases Increasing evidence suggests that the overexpression of DNMTs is implicated in renal fibrosis, tubular degeneration, podocyte injury, and the progression of urological cancers. Therefore, a comprehensive investigation into the function and regulatory mechanisms of DNMTs in urinary system diseases is anticipated to yield novel strategies and targets for their treatment. Consequently, this section provides an overview of the role played by DNMTs in six major urinary system diseases, along with their specific underlying mechanisms. Overview of Urinary System Diseases The urinary system comprises the kidney, ureter, bladder, urethra, as well as the corresponding blood vessels and nerves. Its primary functions encompass filtration, reabsorption, and excretion processes, along with endocrine regulation [37, 38]. Urinary system diseases refer to health conditions that affect the kidneys, ureters, bladder, urethra, and associated structures. These can encompass a range of ailments such as infections, stone formation, tumor development, congenital anomalies, and functional abnormalities [7, 8]. Common symptoms and clinical manifestations of urinary system diseases include pain sensations, alterations in urine characteristics or properties, lower urinary tract symptoms (LUTS), as well as extra‐urinary symptoms [37]. The treatment approaches for urinary system diseases vary depending on the type and severity of the disease. Common therapeutic methods involve drug therapy administration alongside radiotherapy or surgical interventions when necessary [8, 39]. Medical treatments commonly entail antibiotic usage for treating urinary tract infections (UTIs), diuretics for managing edema caused by kidney disease, and immunosuppressants for addressing immune‐related kidney disorders [40]. In certain cases involving specific urinary system diseases like urolithiasis (urinary calculi), prostatic hyperplasia or tumors within the urinary system itself may necessitate surgical intervention [37]. Early detection and diagnosis play a crucial role in managing urinary system diseases effectively by enabling the timely implementation of appropriate treatment measures aimed at alleviating symptoms while preventing complications from arising. Renal Cell Carcinoma RCC is a malignant neoplasm originating from the renal epithelial cells, constituting the predominant subset of renal malignancies [9]. Globally, there is a high incidence rate of RCC, with a slightly higher prevalence among males compared to females (Figure 2). RCC encompasses diverse histological and molecular subtypes, including clear cell carcinoma, papillary carcinoma, and chromophobe carcinoma; however, clear cell renal cell carcinoma (ccRCC) represents the most prevalent subtype, accounting for approximately 70%–80% of cases [9, 41]. Function of DNMTs in renal cell carcinoma (RCC). (a) In normal renal cells, DNMT1, DNMT3A, and DNMT3B are capable of binding to the promoter region of the VEGF gene, thereby facilitating hypermethylation of VEGF and subsequently inhibiting VEGF‐mediated tumor‐related angiogenesis and cellular metastasis. This process can be counteracted by lncRNA IRAIN. (b) In renal cancer cells, DNMT1, DNMT3A, and DNMT3B are capable of mediating CpG island cytosine hypermethylation of tumor suppressor genes VHL, RASSF1A, and PTEN. This process subsequently inhibits DNA damage repair, cell apoptosis, tumor proliferation inhibition, tumor metastasis reduction, as well as a favorable prognosis and outcome. CDK, cyclin‐dependent kinase; HIF‐α, hypoxia‐inducible factor alpha. Image created with Adobe Illustrator (https://www.adobe.com/products/illustrator.html). A recent study demonstrated that the expression levels of DNMT1, DNMT3A, and DNMT3B proteins were significantly higher in ccRCC, papillary RCC, and chromophobe RCC tissues compared to tumor‐free tissues [42]. Furthermore, there was a significant correlation between the expression of DNMTs and various tumor characteristics, including tumor size, pathological stage, histopathological grade, lymph node metastasis, and vascular invasion [42, 43, 44, 45, 46]. Additionally, the observed increase in average methylation of CpG islands facilitated by DNMTs exhibited a significant correlation with the development of diverse macroscopic morphologies, such as tumor protrusion or multinodular growth [47, 48]. Moreover, local DNA hypermethylation at the margin of normal renal tissue can contribute to the progression from precancerous to malignant state [47]. The methylation silencing activity of DNMTs on tumor suppressor genes like von Hippel‐Lindau (VHL), Ras association domain family protein 1 isoform A (RASSF1A), as well as interferon regulatory factor 6 (IRF6) and hypoxia inducible domain family member 1A (HIGD1A) is closely linked to the occurrence and development of RCC [49, 50, 51, 52]. Long noncoding RNAs (lncRNAs) associated with DNMTs function as tumor suppressors in RCC. Normal expression of lncRNA APCDD1L‐AS1 regulates histone expression and inhibits the development of clear cell RCC. However, loss of VHL protein expression due to DNA hypermethylation reduces APCDD1L‐AS1 expression, promoting HCC development [53]. Similarly, lncRNA IRAIN recruits DNMT1, DNMT3a, and DNMT3b to the promoter region of VEGFA to promote promoter methylation, inhibit VEGFA expression, and play a role in tumor suppression [54]. Interestingly, DNMTs‐mediated DNA hypermethylation and oxidative stress contribute to RCC development in patients undergoing dialysis treatment. Hypermethylation of CDK inhibitor family gene cyclin‐dependent kinase inhibitor 2A (CDKN2A) and overexpression of oxidative stress markers such as inducible nitric oxide synthase (iNOS) are common in dialysis‐associated RCC [55]. Renal Fibrosis Renal fibrosis is a pathological condition characterized by the proliferation of fibroblasts and the accumulation of type I collagen and alpha‐smooth‐muscle actin (alpha‐SMA) in renal tissue [56, 57]. It is a common histological feature observed in both renal aging and CKD. The occurrence and progression of renal fibrosis are influenced by abnormal epigenetic modifications of genes susceptible to fibrosis, with DNMTs often playing a role in this process (Figure 3). For instance, the transcription factor Kruppel‐like factor 4 (KLF4) exerts suppressive effects on renal fibrosis, while DNMT1‐mediated hypermethylation directly contributes to its progression [58]. Additionally, excessive production of reactive oxygen species (ROS) can enhance DNMT expression and activity, leading to abnormal hypermethylation of the promoter region of N‐myc downstream regulated gene 2 (NDRG2), a gene that protects against renal fibrosis [59]. Furthermore, alcohol consumption can upregulate DNMT1 expression, resulting in hypermethylation of mothers against decapentaplegic homolog 7 (Smad7). This imbalance between Smad7 and Smad3 caused by reduced levels of Smad7 represents an underlying mechanism for EtOH‐induced renal fibrosis [60]. Multiple signaling pathways mediated by DNMTs in the formation of renal fibrosis. (a) DNMTs suppress the expression of transcription factor KLF4 by mediating promoter hypermethylation, thereby promoting epithelial–mesenchymal transition and contributing to the development of renal fibrosis; (b) oxidative stress can upregulate the levels of DNMTs, which in turn promote NDRG2 hypermethylation and activate the wnt/β‐catenin signaling pathway, leading to renal fibrosis progression; (c) alcohol enhances DNMT‐mediated methylation of Smad7 promoter, resulting in an imbalance between Smad7 and Smad3 that promotes renal fibrosis progression; (d) genistein and other natural plant components have the ability to inhibit DNMTs‐mediated hypermethylation of Klotho gene promoter, thus blocking downstream wnt/β‐catenin signaling pathway and TGF‐β/Smad signaling pathway activation, ultimately inhibiting renal fibrosis development. However, TGF‐β inhibits the expression of miR‐152 and miR‐30a molecules that act as inhibitors for DNMTs, thereby enhancing their activity. Mito‐TEMPO, mitochondria‐targeted‐antioxidants; Nox2/4, NADPH oxidase 2/4; ROS, reactive oxygen species. Image created with Adobe Illustrator (https://www.adobe.com/products/illustrator.html). The transmembrane protein Klotho‐related β‐glucuronidase (Klotho) is a multifunctional factor that not only exhibits antiaging properties with antioxidant capacity but also plays a crucial role in inhibiting renal fibrosis [56]. Abnormal elevation of DNMT1/3a/3b leads to hypermethylation of the Klotho gene promoter, which is significantly associated with the development of renal fibrosis [61]. Dihydroartemisinin (DHA) effectively reduces DNMT1 expression and reverses hypermethylation of the Klotho promoter, subsequently restoring normal Klotho expression and mediating inhibition of the downstream Wnt/β‐catenin and TGF‐β/Smad signaling pathways, thereby exerting renoprotective effects [62]. Apart from DHA, natural plant components such as genistein, curcumin, rhein, and DNMT inhibitor zebularine can protect Klotho and inhibit the progression of renal fibrosis by alleviating hypermethylation of its promoter [63, 64, 65, 66]. Therefore, DNMTs and Klotho play a pivotal role in renal fibrosis. Additionally, TGF‐β and microRNA are also involved in DMNTs‐mediated renal fibrosis. TGFβ enhances DNMT1 and DNMT3a levels by inhibiting miR‐152 and miR‐30a in renal cells and fibrotic kidneys while reducing Klotho expression to promote renal fibrosis [67]. Interestingly, chronic hypoxia is associated with methylation‐induced silencing of Klotho expression as well. Reversal of hypoxia alleviates renal fibrosis by promoting demethylation at the Klotho promoter [68]. Meanwhile, recent studies have shown that hypermethylation of microRNA219a‐2 and a significant reduction in microRNA‐219a‐5p expression in unilateral ureteral obstruction (UUO) or renal fibrosis induced by renal ischemia–reperfusion can be detected by genome‐wide DNA methylation analysis and pyrophosphate sequencing. Functionally, overexpression of microRNA219a‐2 appeared to enhance fibronectin induction during TGF‐β1 treatment, leading to the finding that hypermethylation of microRNA219a‐2 may attenuate the expression of microRNA‐219a‐5p and induce the upregulation of its target gene, ALDH1L2, which reduces fibronectin deposition by inhibiting PAI‐1, and reduce fibronectin deposition by inhibiting PAI‐1. This study suggests that the regulation of microRNA219a‐2 by DNA methylation may play an important role in the development of renal fibrosis [69]. Chronic Kidney Disease CKD is a progressive condition characterized by the gradual decline of renal function, which cannot be restored to normal levels [70]. In CKD, inflammation and apoptosis mediated by DNMTs play crucial roles in epigenetic modifications. It is widely recognized that patients with CKD often exhibit hyperhomocysteinemia, a condition where elevated levels of homocysteine are present. Homocysteine has been shown to inhibit the activity of DNMT1, leading to reduced DNA methylation of CD40 promoter and promoting the differentiation of inflammatory CD40+ monocytes [71]. Furthermore, homocysteine can also induce hypermethylation of miR‐1929‐5p and miR‐30a‐5p promoters, which are associated with inhibition of podocyte apoptosis, through upregulation of DNMT1 expression [72, 73]. Interestingly, DNMT1 has also been implicated in endogenous retroviruses (ERVs) in CKD. Genetic deletion or pharmacological inhibition of DNMT1 induces ERV expression, and subsequent overexpression in renal tubular cells promotes renal fibroinflammation [74]. Klotho deficiency also plays a crucial role in CKD. For instance, the accumulation of uremic toxins can induce the expression of DNMTs, which participate in the silencing of Klotho through hypermethylation and promote CKD progression [75]. Additionally, epigenetic modification of Klotho may serve as a significant pathological mechanism for vascular calcification in CKD [76]. It is noteworthy that rhein, apart from its role in diabetic nephropathy, can also reverse Klotho deficiency in CKD and exert a protective effect on the kidneys [77]. Another notable characteristic of CKD is the reduced secretion of erythropoietin (EPO) under specific conditions. EPO is secreted by renal erythropoietin cells (REPCs) [78]. Although REPCs are retained within the kidneys of patients with CKD, they fail to produce sufficient EPO upon hypoxic stimulation. It has been observed that DNMT‐mediated hypermethylation of the EPO gene is significantly upregulated in renal myofibroblasts, while TGF‐β1, a pro‐fibrotic factor, can induce hypermethylation of the EPO gene in pericytes [79, 80]. Therefore, dysregulation of EPO in CKD is closely associated with DNMTs. Acute Kidney Injury Acute kidney injury (AKI) is a common clinical syndrome and a major complication in hospitalized patients, with more than 50% of intensive care patients experiencing AKI. The incidence of AKI has been on the rise globally over the past few years, with an in‐hospital mortality rate of up to 20%, but there is currently no effective preventive or therapeutic strategy for AKI. A growing number of studies have shown that epigenetic regulation plays an important role in the process of AKI, which may involve histone modification, DNA methylation, and significant changes in the expression of various noncoding RNAs. The role of microRNAs in the development of AKI has been investigated quite extensively, and a large number of studies have demonstrated that a variety of specific microRNAs are associated with AKI pathogenesis, suggesting that microRNAs are involved in the pathogenesis of AKI. A large number of studies have demonstrated that a variety of specific microRNAs are associated with the pathogenesis of AKI, suggesting that microRNAs may become novel diagnostic biomarkers for AKI [81]. For example, increased levels of histone acetylation appear to protect the kidney from AKI damage and promote renal repair. Recent studies suggest that AKI may also be associated with genome‐wide and gene‐specific DNA methylation changes; for example, the proapoptotic factor interferon regulatory factor 8 (Irf8) was identified as a hypomethylated gene in cisplatin‐induced AKI. In rat renal proximal tubular cells, knockdown of Irf8 inhibited cisplatin‐induced apoptosis, and this result demonstrated the pro‐death role of Irf8 in renal tubular cells, signifying that Irf8 may be an important factor contributing to the development of AKI by decreasing the DNA methylation level [82]. Meanwhile, as a member of the TET family, Tet1 has been shown to reduce the 5mC levels of the Sod1 and Sod2 promoters to promote their expression in an enzyme activity‐dependent manner, thereby reducing injury‐induced excessive ROS and decreasing I/R or UUO injury. In addition, Tet1 knockout mice showed increased renal injury and renal cell death, increased ROS accumulation, G2/M cell cycle arrest, inflammation, and fibrosis, and the findings may provide a new direction to explore the pathological process of AKI [83]. As for clinical drugs, some studies have shown that the administration of crotonate can prevent nephrotoxic AKI, but the therapeutic effect of DNA methylation inhibitors in AKI is still in conflict with physiological toxicity [84]. Thus, the role and regulatory mechanisms of DNA methylation in renal injury and repair remain largely elusive. However, with the rapid development of protein structure editing technology, perhaps in the future we can mitigate AKI and other related diseases by editing DNMT isoform structure inhibitors so that they can further regulate the process of DNA methylation without endangering the normal physiological processes in the body. Diabetic Fidney Disease With the current socioeconomic status undergoing changes and an increasing aging trend in the population, diabetic kidney disease (DKD) has emerged as a leading cause of CKD [85]. Given its significance, we have distinguished DKD from CKD and provided a detailed account of its association with DNMTs (Figure 4). Role of DNMTs in the formation and progression of diabetic kidney disease. The DNMTs play a role in inducing hypermethylation of diabetes‐related genes, leading to renal vascular damage in diabetic kidney disease. Moreover, they are also involved in podocyte injury and kidney inflammation, thereby promoting the development and progression of diabetic nephropathy. GBM, glomerular basement membrane; Me, methylation. Image created with Adobe Illustrator (https://www.adobe.com/products/illustrator.html). The global prevalence of type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) has witnessed a rapid increase over the past three decades [12]. DKD, a highly prevalent complication of diabetes mellitus, involves the accumulation of extracellular matrix, hypertrophy, and damage to glomerular and tubular cells, ultimately leading to end‐stage renal disease [86, 87]. Emerging evidence suggests that DNA methylation and its associated epigenetic mechanisms may play a pivotal role in the pathogenesis and progression of diabetic nephropathy; however, further investigations are required to elucidate the specific molecular mechanisms and regulatory networks. DKD can be accompanied by the demethylation and hypermethylation of various genes. For instance, in diabetic mice, abnormal hypomethylation of angiotensinogen (Agt), ATP‐binding cassette subfamily C member 4 (Abcc4), cytochrome P450‐family 4‐subfamily a‐polypeptide 10 (Cyp4a10), glucose transporter 5 (Glut5), and metformin (Met) was observed along with hypermethylation of kinesin family member 20B (Kif20b), claudin‐18 (Cldn18), and solute carrier organic anion transporter family member 1A1 (Slco1a1) [88]. DNMTs are typically involved in the hypermethylation of these genes, and their expression levels are significantly correlated with diabetic nephropathy [89]. Overexpression of DNMTs in podocytes can result in the hypermethylation of nephrin, glutamate receptor ionotropic AMPA type subunit 3 (GRIA3), calcineurin 1 regulatory factor (RCAN1), and actin α 4 (ACTN4), among others [90, 91, 92, 93]. The decreased expression of these factors will exacerbate podocyte apoptosis and loss, leading to the occurrence of proteinuria in DKD. In addition, the upregulation of DNMT1 in podocytes, mediated by nuclear factor Sp1 and nuclear factor κB (NF‐κB), also contributes to the hypermethylation‐induced reduction of podocyte motility, glomerular hypertrophy, mesangial matrix expansion, and podocyte injury [94]. Importantly, the upregulation of DNMT1 expression leads to the significant methylation of the promoters of negative regulators of mammalian target of rapamycin (mTOR), such as phosphatase and tensin homolog (PTEN) and tuberous sclerosis complex 2 (TSC2), resulting in pathogenic activation of the mTOR pathway and subsequent inflammation in diabetic kidneys [95]. It is worth noting that DKD does not exclusively affect podocytes; rather, it involves the upregulation of DNMT1 and DNMT3a in proximal tubular epithelial cells stimulated by high glucose, which leads to a reduction in transmembrane protein endoplasmic reticulum‐interacting protein 24 (EI24). The inhibition of EI24 promotes epithelial–mesenchymal transition (EMT) in renal tubular cells through the AMPK signaling pathway, ultimately contributing to diabetic kidney injury [96]. Klotho is a crucial renoprotective factor in DKD. Baicalin has the potential to mitigate diabetic kidney injury in diabetic nephropathy by regulating Klotho promoter methylation [97]. Furthermore, rhein treatment also demonstrates effectiveness in rectifying the significant induction of Klotho promoter hypermethylation caused by DNMTs [77]. Bladder Cancer Bladder cancer (BCa) is one of the most prevalent malignant tumors in the urinary system, originating from the bladder wall and categorized into non‐muscle‐invasive and muscle‐invasive types [98]. The occurrence and progression of BCa are closely associated with DNMT‐induced hypermethylation of multiple gene promoters. Promoter hypermethylation of death‐associated protein kinase (DAPK), a regulator of apoptosis, is strongly linked to early recurrence in superficial BCa [99]. Upregulation of DNMTs inhibits maspin, a member of the serine protease inhibitor family, leading to BCa progression [100]. Gene hypermethylation of Foxa1, an important transcription factor belonging to the forkhead box family, promotes BCa development [101]. Multiple cancer suppressor genes, such as PTEN, CDKN2A, and opioid‐binding protein/cell adhesion molecule‐like (OPCML), undergo significant silencing after DNMT‐induced hypermethylation [101, 102, 103]. Low levels of cancer suppressor genes positively correlate with BCa progression; thus, these genes hold potential prognostic significance as epigenetic biomarkers for urothelial carcinoma in the bladder. Additionally, microRNAs also play a role in mediating crosstalk between DNMTs and BCa: miR‐148a‐3p inhibits proliferation and EMT by suppressing DNMT1 activity in BCa cells; miR‐124‐3p targets DNMT3B to inhibit proliferation, migration, and invasion, while promoting apoptosis in BCa cells; and miR‐152 hinders PTEN promoter CpG methylation mediated by DNMT1, thereby impeding BCa progression [104, 105, 106]. Prostate Cancer Prostate cancer, typically originating from epithelial cells in the prostate gland, is a prevalent malignancy among elderly males. In recent years, there has been a significant increase in the incidence of prostate cancer, with noticeable regional and racial disparities [107]. DNMTs play a crucial role in the initiation, progression, transformation, and metastasis of prostate cancer by hypermethylating CpG islands within gene promoters or mediating associated biological processes [108]. Glutathione S‐transferases P1 (GSTP1) encodes glutathione S‐transferase, and its transcriptional silencing through DNMTs‐mediated CpG island hypermethylation results in the loss of its “caregiver” function, leaving prostate cells inadequately protected against oxidants and electrotropic carcinogens [109]. Furthermore, DNMTs can also facilitate promoter hypermethylation of tumor suppressor genes such as RASSF1A, collapsin response mediator protein 4 (CRMP4), deleted in liver cancer 1 (DLC‐1), WW domain‐containing oxidoreductase (WWOX), and aldehyde dehydrogenase 1 family member A2 (ALDH1a2) to promote prostate cancer progression [110, 111, 112, 113, 114]. Targeting these suppressor genes may provide new insights into mechanistic studies of cancer biology. Another study revealed that TGF‐β induces DNMTs expression in prostate cancer cells, and levels of TGF‐β and DNMTs are correlated with invasive potential [115]. MicroRNAs also participate in the interplay between DNMTs and prostate cancer; for instance, miR‐145 sensitizes prostate cancer cells to X‐ray radiation therapy by inhibiting DNMT3b expression [116]. Interestingly, DNMTs interact spatially and temporally with polo‐like kinase 1 (PLK1) in prostate cancer cells, and combining PLK1 inhibitors with DNMT inhibitors exerts a more potent inhibitory effect on advanced disease, potentially via interference with autophagy‐related regulation [117]. Urolithiasis In the context of urolithiasis, DNMTs exert a pivotal influence. Upon exposure to calcium oxalate monohydrate (COM), the expression levels of DNMT1, DNMT3a, and DNMT3b at both the mRNA and protein levels are markedly elevated. This elevation triggers changes in DNA methylation patterns, which in turn cause the downregulation of ATP1A1. The diminished expression of ATP1A1 facilitates the activation of related signaling pathways, thus enhancing crystal–cell adhesion and driving the progression of stone formation [118]. Benign Prostatic Hyperplasia In the urinary system, 5‐α reductase type 2 (SRD5A2) has been confirmed to be a key enzyme in prostate development and growth. Clinically, finasteride, which inhibits SRD5A2, is commonly used to treat urinary obstruction caused by benign prostatic hyperplasia. Related studies have shown that the methylation of SRD5A2 is regulated by DNMT1, and inflammatory mediators such as tumor necrosis factor α, NF‐κB, and IL‐6 regulate the expression of DNMT1, thereby affecting the methylation of the SRD5A2 promoter and gene expression. Artificially inducing inflammation in primary prostate epithelial cells leads to high methylation of the SRD5A2 promoter, resulting in the silencing of SRD5A2, while tumor necrosis factor α inhibitors can reactivate SRD5A2 expression. Therefore, SRD5A2 expression is not static and is widely present in benign adult prostate tissue. Its high expression often indicates prostate hyperplasia, which can lead to urinary tract obstruction and other urological diseases [119]. DNA Methylation in the Diagnosis and Treatment of Urological Diseases In recent years, the incidence of urological diseases has been increasing, posing a major challenge to global public health. As more studies reveal a close association between DNA methylation and the pathogenesis of urological diseases, the detection of DNA methylation‐related markers may serve as important biomarkers and therapeutic targets. This section will explore the potential applications of DNA methylation markers in this field. BCa‐Specific Methylation Markers in the Diagnosis of BCa BCa, as a malignant tumor that is prevalent worldwide, has a fairly high mortality rate. Current screening methods for its diagnosis and follow‐up mainly include cystoscopy and urine exfoliative cytology testing, but these methods have the disadvantages of high invasiveness, low sensitivity, and low specificity. The close relationship between DNA methylation modification and tumorigenesis and the presence of DNA associated with BCa in urine make DNA methylation‐related urinary biomarkers useful in early diagnosis, recurrence monitoring of BCa, and risk stratification. Emerging research has proposed an effective method called utMeMA for detecting urinary tumor DNA methylation in multiple genomic regions by MassARRAY. Compared to urine cytology and FISH, the utMeMA‐based assay shows a significant improvement in sensitivity. Urine diagnostic scores from this assay correlate better with tumor malignancy and load. Although this type of assay has the advantages of being noninvasive, convenient, economical, and highly sensitive, its large‐scale promotion and application still need to be validated by prospective, large‐sample clinical studies. In the context of precision medicine, artificial intelligence technology, and the significant development of the epigenetic landscape of cancer, the application value of DNA methylation‐related urine biomarkers in the diagnosis and treatment of BCa will be gradually highlighted. They developed and validated a diagnostic model based on two biomarkers, which can distinguish patients with bladder cancer (BCa) with high accuracy (86.7%), sensitivity (90.0%), and specificity (83.1%). Additionally, utMeMA‐based detection showed a significant improvement in sensitivity compared to urine cytology and FISH, especially in early detection (stage Ta and low‐grade tumor, 64.5% vs. 11.8%, 15.8%), minimal (81.0% vs. 14.8%, 37.9%), residual (93.3% vs. 27.3%, 64.3%), and recurrent (89.5% vs. 31.4%, 52.8%) tumors [120]. Application of DNA Methylation Markers of Urine and Urine Sediment in the Diagnosis of Uroepithelial Carcinoma Uroepithelial carcinoma is a malignant tumor that occurs in the uroepithelium of the urinary system, and it is relatively common among urological tumors, but the exact cause has not been clarified due to its high recurrence rate and high postoperative surveillance. Certain FDA‐approved tools (e.g., urine cytology and cystoscopy) are used to detect UC, but have the disadvantages of being inaccurate, invasive, and expensive. Recent studies have identified extended analyses by combining all methylation and protein markers (up to five markers in total) for identifying patients with UCa in a heterogeneous collective of cancer‐free individuals and patients with urological or gynecological cancers. Combining various biomarkers at the protein and DNA level provides a new option for noninvasive UCa diagnosis in urine and may therefore help to reduce the number of unnecessary cystoscopies, especially in patients with no history of UCa [121]. Currently, many studies have focused on diagnostic models for UC, but most of them are based on a single feature, such as methylation changes or copy number variants, with poor specificity or sensitivity, especially for early‐stage, low‐grade, and microscopic residual UC. Therefore, there is an urgent need for a sensitive, noninvasive, convenient, and affordable technique to replace these conventional methods to some extent. A recent study proposes an enhanced method called “UCseek” for the detection of multiple DNA methylation markers in urinary sediment, which showed potential clinical feasibility with a sensitivity and specificity of 92.7% and 90.7%, respectively, in an independently validated set of comparative analyses of large data. In addition, UCseek also has good diagnostic performance for low‐grade and early‐stage UC, which may reduce the burden of cystoscopy on patients [122]. 5hmC Levels in DNA Methylation Reflect Prognosis, Survival, and Staging of Urological Tumors DNA methylation is an abundant and stable epigenetic modification, and in active genomic regions, DNA methylation can be reversed by TET (Ten‐11 translocation) enzymes, which are responsible for fine‐tuning the methylation pattern. TET enzymes oxidize the methyl group of 5mC to produce 5‐hydroxymethylcytosine (5hmC) and other oxidized methylcytosines, promoting passive and active demethylation. A growing number of studies have shown a more significant association between 5hmC levels and the presence of healing, survival, and staging of urological tumors. For example, 5hmC levels in tumor tissue are an independent prognostic marker for renal cancer, with lower 5hmC levels associated with shorter overall survival. In addition, deletion of 5hmC was associated with hypermethylation in tumors compared to matched normal tissues, particularly in the gene body region. Strikingly, gene body hypermethylation was significantly associated with the silencing of tumor‐associated genes. Downregulation of IDH1 was identified as a mechanism for 5hmC deletion in renal cancer. In a xenograft model, restoration of 5hmC levels attenuated the invasive capacity of tumor cells and inhibited tumor growth. Therefore, by remodeling DNA methylation patterns, 5hmC deletion is both a prognostic marker and an oncogenic event in renal cancer. For continuous monitoring of 5hmC levels, it may become an important tool to diagnose the healing effect and recurrence rate of renal cancer. However, the mechanism of the role of 5hmC levels in DNA methylation in other urological tumors has not been fully revealed and may become a hot spot for scientific research in the future [123]. Application of DNMTs as Potential Biomarkers in the Diagnosis of Urinary System Diseases Accurate and prompt diagnosis of urinary system diseases is crucial for the treatment and rehabilitation of patients. However, current clinical detection methods have certain limitations, including a lack of specificity, sensitivity, and inadequate early diagnostic capabilities. Therefore, the identification of novel biomarkers for diagnosing urinary system diseases has become a focal point in current research endeavors. In recent years, DNMTs, as a class of pivotal epigenetic regulatory enzymes, have demonstrated potential application value in diagnosing various diseases, particularly urinary system diseases. The expression levels of DNMT1, DNMT3A, and DNMT3B were found to be higher in RCC compared to nontumor tissues. Furthermore, the expression levels of DNMT1, DNMT3A, and DNMT3B exhibited significant correlations with tumor size, tumor pathological stage, histopathological grade, lymph node metastasis, and vascular invasion [42, 47]. In renal fibrosis, the expression levels of DNMTs have been closely associated with fibroblast proliferation, extracellular matrix remodeling, type I collagen accumulation, alpha‐SMA expression, renal aging, and even chronic renal failure [61, 124]. In diabetic kidney injury or diabetic nephropathy, DNMTs are closely associated with podocyte apoptosis, mesangial cell proliferation, reduction of Klotho expression, impaired podocyte motility, EMT in renal tubular cells, and renal inflammation [89, 94, 95]. In CKD, DNMTs are implicated in decreased secretion of EPO, renal fibrosis, vascular calcification, hyperhomocysteinemia, podocyte damage, and apoptosis [71, 76, 79]. In bladder and prostate cancer cases, DNMTs play a role in promoting tumor cell proliferation, EMT induction, early tumor recurrence risk elevation, as well as facilitating tumor tissue infiltration and metastasis [99, 115, 125, 126]. It can be concluded that DNMTs hold promising potential as valuable biomarkers for diagnosing urinary system diseases. Through further research and validation efforts, DNMTs may evolve into powerful tools for early diagnosis and treatment monitoring of urinary system diseases to ultimately enhance patient outcomes and survival rates. Application of DNMT Inhibitors as Potential Therapies in Urinary System Diseases DNMTs play a crucial role in the pathogenesis and progression of urinary system disorders; thus, inhibitors targeting DNMTs are regarded as a promising therapeutic strategy. Multiple inhibitors of DNMTs, particularly the FDA‐approved 5‐aza‐2′‐deoxycytidine (DAC) and 5‐azacytidine (AZA), have been investigated for their potential in treating various urinary system diseases [33, 127]. Among them, DAC has been extensively studied for its efficacy in BCa treatment. Research has demonstrated that DAC application can reverse epigenetic alterations caused by DNA methylation, such as the silencing of RASSF1A gene expression, thereby enhancing the sensitivity of BCa cells to chemotherapy drugs [128]. Furthermore, DAC promotes immune‐related pathway activation and IL‐6 release through DNA hypomethylation of the NOTCH1 signaling pathway, facilitating epigenetic reprogramming and differentiation of muscle‐invasive bladder cancer (MIBC) tumor cells. It is worth noting that in other tumor microenvironments, IL‐6 release is generally considered to be protumorigenic; however, in BCa, overexpression of IL‐6 reduced the motility and invasion of MIBC cells in vitro [129]. The combination of DAC with other drugs or therapies also holds significant promise for the treatment of BCa. Combining DAC with histone deacetylase inhibitors, immune agents, conventional chemotherapy, and CAR‐T therapy demonstrates a more potent anti‐BCa effect [130, 131, 132, 133]. Overall, the application of DNMT inhibitors as potential therapies in urinary system diseases shows great potential; however, further clinical studies are required to validate their safety and efficacy. In the future, treatment strategies based on DNMT inhibitors are expected to offer novel perspectives and options for managing urinary system diseases while providing increased hope and opportunities for patients. Conclusion and Future Expectation In basic and clinical research on urinary system diseases, DNA methylation has long been recognized as a key epigenetic regulatory mechanism, with DNMTs playing a central role. DNMTs, as vital epigenetic enzymes, regulate gene expression by mediating the methylation of gene promoters. They exhibit unique regulatory functions in various urological diseases, including RCC, renal fibrosis, diabetic nephropathy, chronic renal failure, AKI, BCa, and prostate cancer. In‐depth studies may clarify the link between DNA methylation and these diseases. DNMTs also hold potential as diagnostic biomarkers, and their inhibitors could serve as therapeutic interventions. However, the exact mechanisms of DNMTs in urological diseases remain unclear. Only a few epigenetic drugs are currently approved for cancer treatment, and the roles of DNMT isoforms in tumorigenesis and their interactions with tumor tissues need further investigation. Future research should focus on DNMT isoforms to understand their conformational changes and effects on gene expression. Clinical trials and large‐scale studies are necessary to validate DNMTs as biomarkers and therapeutic targets. In recent years, spatial transcriptome and single‐cell sequencing technologies have developed rapidly and have been applied in a large number of life sciences, and single‐cell technologies can reveal the heterogeneity of intercellular transcriptomes in various tissues. Simultaneous analysis of the transcriptome and DNA methylome at the single‐cell level might deepen our understanding of how DNA methylation heterogeneity contributes to transcriptomic and functional heterogeneity of urological tissues and cells and thus better explore the role of DNA methylation in urological diseases and their interrelationships with related tissues, as well as how to use methylation transferase to regulate the process. For example, the kidney is a complex three‐dimensional organ, and the spatial and molecular principles underlying its diseases are still not well understood. Spatial transcriptomics can be used to collect high‐quality datasets, including single‐cell, single‐nuclear, spot‐level (Visium), and single‐cell resolution (CosMx) spatial‐RNA expression, as well as single‐nuclear open chromatin, capturing cells from healthy, diabetic, and hypertensive human kidneys. By combining these data, we can identify cell types and map them to their locations within the tissue. Unbiased deconvolution of spatial data has identified four distinct microenvironments: glomerular, immune, tubule, and fibrotic. Integrating different spatial data with DNA methylation data may represent a significant breakthrough in the future exploration of therapeutic targets and may achieve better prognostic outcomes compared to traditional histopathology. To sum up, DNMTs are of great significance in the diagnosis and treatment of urological diseases. A thorough investigation into DNA methylation, as well as the function and regulatory mechanisms of DNMTs, can deepen our understanding of the pathogenesis of urological diseases and also aid in the creation of more accurate diagnostic methods and personalized therapeutic strategies. Author Contributions Wei Dong: writing – original draft, writing – review and editing, visualization. Shengbin Pei: writing – original draft, writing – review and editing. Dacheng Zhu: writing – original draft, visualization. Cheng Zeng: writing – review and editing, visualization. Yue Qiu: visualization. Yuxin Wu: supervision, visualization. Xinlu Jia: visualization, software, supervision. Siqi Zhang: data curation, visualization. Chao Li: visualization, writing – review and editing. Wenjuan Zhang: writing – review and editing. Wenbing Zhang: funding acquisition, writing – review and editing. Zhihua Chen: review and editing. Ethics Statement The authors have nothing to report. Consent The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest. Acknowledgments We thank alumnus Jiajin Li (Anhui Medical University, Hefei, China) for the critical reading of our manuscript. Dong W., Pei S., Zhu D., et al., “The Role of DNA Methyltransferases in Urinary System Diseases,” Cancer Innovation 0 (2025. 4:): 1–19. 10.1002/cai2.70034. Wei Dong, Shengbin Pei, Dacheng Zhu, and Cheng Zeng contributed equally. Contributor Information Wenjuan Zhang, Email: zhangwenjuan0603@126.com. Wenbing Zhang, Email: zwb0945@163.com. Zhihua Chen, Email: czh19821127@163.com. Data Availability Statement Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study. References Associated Data Data Availability Statement Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.